Recent studies have demonstrated the ability to specifically deliver mRNA to the placenta through ionizable lipid nanoparticle (LNP) technology to treat placental disorders such as pre-eclampsia.43 Future investigations could focus on applying the cutting-edge mRNA-LNP platform to effectively deliver IL-27 to the placenta and enhance antiviral responses in vivo. Here, IL27 is linked to placenta disorder.